Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICPROIRI: Irinotecan Liposomes + Cetuximab + Vemurafenib in BRAF-mutated mCRC
NCT06763029Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome injection in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06763029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763029.